Biogen
Statement: Global Alzheimer’s Platform Foundation Praises FDA for Aducanumab Approval
/Patients and Doctors Deserve the Ability to Consider Whether Aducanumab Will Deliver the Best Medical Outcome and Quality of Life Washington, DC (June 7, 2021) – John Dwyer, President of the Global Alzheimer’s Platform Foundation (GAP), a patient-centric organization committed to accelerating the discovery of therapies for the treatment of Alzheimer’s, issued the following statement on […]
Read more »